SYDNEY, AUSTRALIA; BERLIN and NEW CANAAN, CT--(Marketwire - October 29, 2007) - A symposium on platinum resistant ovarian cancer held at the European Society for Gynecological Oncology in Berlin on Sunday, 28 October has confirmed the need for an effective chemosensitizing drug to support new platinum treatment regimens in resistant ovarian cancer. Leading cancer researchers speaking at the symposium described advances in platinum therapies and expressed enthusiasm for phenoxodiol as a promising new investigational drug as part of a new approach for this indication.
